news

CUPERTINO, Calif., Feb. 7 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that the company expects to complete enrollment of its 50 patient Phase II clinical trial for the company’s lead product, DUROS sufentanil, ahead of the previously anticipated date for completion of enrollment. DUROS sufentanil is designed to deliver sufentanil on a continuous basis […]

CUPERTINO, Calif., Jan. 24 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Evelyn R. Robledo has been promoted to Vice President of Quality Assurance and Compliance. Ms. Robledo joined DURECT in March 2000 and, utilizing her solid understanding of FDA regulations, developed and implemented an effective Quality Assurance System to support DURECT’s product development

CUPERTINO, Calif., Jan. 22 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) fourth quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, February 15, 2001 at 4:30 p.m. EST with Jim Brown, President and Chief Executive Officer, Tom Schreck,

CUPERTINO, Calif., Dec. 12 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will present a company overview and discuss the Phase II trial in progress for its lead product, DUROS sufentanil for the treatment of chronic pain, at the 19th Annual Healthcare Conference to be held January 9, 2001 at 2:00 P.M. in

CUPERTINO, Calif., Dec. 11 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced enrollment of the patients into a Phase II clinical trial for the company’s lead product, DUROS sufentanil, for the treatment of chronic pain. DUROS sufentanil uses the DUROS osmotic delivery system to deliver sufentanil on a continuous basis for 3 months. Sufentanil is

CUPERTINO, Calif., Nov. 13 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2000. DURECT’s net loss attributable to common stockholders for its third quarter ended September 30, 2000 was $6.0 million dollars, or $0.62 cents per diluted share, compared to a net loss of $2.4 million

CUPERTINO, Ca., Nov. 7 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) third quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, November 13, 2000 at 4:30 p.m. EST with Jim Brown, President and Chief Executive Officer, Tom Schreck,

CUPERTINO, Calif., Nov. 2 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that the underwriters of its recent initial public offering of common stock have exercised their over-allotment option in part and purchased an additional 700,000 shares at the initial public offering price of $12.00 per share. All of the over-allotment shares were sold by

CUPERTINO, Calif., Oct. 23 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it has commenced construction of a commercial manufacturing facility that is expected to meet DURECT’s production needs for Phase III clinical trials currently planned for late 2001 and commercial market supply for its lead product, DUROS sufentanil. The new facility will comprise

CUPERTINO, CA, September 28, 2000 – DURECT Corporation today announced the initial public offering of 7,000,000 shares of its Common Stock at a price to the public of $12 per share. Durect Corporation’s Common Stock will be listed on the NASDAQ National Market under the symbol “DRRX” and will begin trading on September 28, 2000.